E. Knaus
Pharmacology · 2008
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Pharmacology — 13 citations into it
Whom E. Knaus trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- W. Frishman (in Pharmacology)
Papers from E. Knaus's perspective
Ordered by how strongly the researchers E. Knaus trusts endorse each paper. Same corpus, a different order for every researcher.
- Cyclooxygenases: structural, cellular, and molecular biology. (Annual Review of Biochemistry)
- Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases (Nature reviews. Drug discovery)
- The coxibs, selective inhibitors of cyclooxygenase-2. (New England Journal of Medicine)
- 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. (Journal of Medicinal Chemistry)
- Risk of cardiovascular events associated with selective COX-2 inhibitors. (Journal of the American Medical Association (JAMA))
- COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression (Proceedings of the National Academy of Sciences of the United States of America)
- Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. (Circulation)
- Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. (New England Journal of Medicine)
- Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration (Proceedings of the National Academy of Sciences of the United States of America)
- The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* (Journal of Biological Chemistry)